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Background: Signiﬁcant efforts have been focused on investigating the contribution of common variants
to Parkinson disease (PD) risk. Several independent GWAS and metanalysis studies have shown
a genome-wide signiﬁcant association of single nucleotide polymorphisms (SNPs) in the a-synuclein
(SNCA) and microtubule-associated protein tau (MAPT) regions. Here we investigated the role of SNCA
and MAPT as PD susceptibility genes in a large Italian population of 904 patients and 891 controls. An
evaluation of geneegene and gene-environment interactions in association with PD was also attempted.
Methods: The SNCA Rep1 microsatellite was genotyped by a ﬂuorescent PCR assay, whereas the SNPlex
genotyping system was used to genotype 12 additional markers across the SNCA gene, and 2 SNPs
tagging the risk MAPT H1 haplotype.
Results: Single-marker analysis demonstrated nominal evidence of association for: i) the 261-bp-long
allele of Rep1; ii) 7 SNPs in the SNCA region (top SNP: rs356186, P ¼ 3.08  1004, intron 4); iii) both SNPs
identifying the MAPT H1 haplotype (P ¼ 4.63  1004 and P ¼ 4.23  1004 for rs1800547 and rs9468,
respectively). Moreover, we found a highly signiﬁcant protective haplotype spanningw83 kb from intron
4 to the 30 end of SNCA (P ¼ 1.29  1005).
Conclusions: Our ﬁndings strongly conﬁrm SNCA andMAPT as major PD susceptibility genes for idiopathic
PD in the Italian population. Interaction analyses did not evidence either epistatic effects between the
two loci or gene-environment interactions.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Parkinson disease (PD; OMIM#168600) is the second most
common neurodegenerative disorder after Alzheimer disease, with
a lifetime risk of developing the disease of 1e5% [1]. Up to now, ﬁve
major causative genes have been identiﬁed in Mendelian forms
(SNCA, PRKN, DJ1, PINK1, LRRK2), although mutations in these genes
collectively explain less than 10% of familial PD cases [2]. In the vast
majority of sporadic cases, the etiology is probably more complex,
resulting from a combination of multiple environmental exposures
(e.g.: pesticides, coffee consumption, cigarette smoking) and
genetic risk factors acting on a background of aging. Indeed, a largeand Genetics for Medical
3 Milano, Italy. Tel.: þ39 02
ta).
-NC-ND license.amount of research has focused on identifying genetic variability
that confers PD susceptibility [2].
Among putative PD susceptibility genes, both the a-synuclein
gene (SNCA) and the microtubule-associated protein tau gene
(MAPT) have been repeatedly investigated [3].
SNCA was the ﬁrst causal gene identiﬁed in familial PD [3], and
encodes a-synuclein, a major component of Lewy bodies (LB),
a pathologic hallmark of PD [2]. The overproduction of a-synuclein is
thedirect causeof LBaccumulation inneural cells of familial PDcases,
whereas a more subtle overproduction of otherwise normal a-syn-
uclein may contribute to PD pathogenesis in sporadic patients [2].
Rep1 (GenBank D4S3481) is a complex polymorphic micro-
satellite repeat located w10 kb upstream of the translation start
site of SNCA. While several studies suggested that speciﬁc SNCA
Rep1 alleles are associated with late-onset idiopathic PD, others
have observed no association or reported an inverse association
between the risk allele and PD ([4,5] and references therein). After
many small studies, Maraganore and colleagues ﬁnally conﬁrmed
the association between the Rep1 polymorphism and PD in a large
L. Trotta et al. / Parkinsonism and Related Disorders 18 (2012) 257e262258meta-analysis using more than 5000 samples from 11 different
sites [5]. Moreover, functional analyses on the two most common
Rep1 alleles (261 bp and 259 bp) suggested that the 261 bp-long
risk allele is associated with an up-regulation of SNCA expression,
whereas the 259 bp-long protective variant shows reduced gene
expression [6e8].
In addition to variability in the promoter, genetic variation in the
30 untranslated region of SNCA has been proposed to modulate
predisposition to PD [9]. Association of haplotypes within linkage
disequilibrium (LD) blocks located in the 30 end of SNCA with
sporadic PD has been reported [10,11]. Interestingly, a recent paper
by Mata and colleagues showed a possible association between
a single nucleotide polymorphism (SNP), rs356219, in the 30 region
of the gene and SNCA plasma levels [12].
MAPTencodes for themicrotubule-associated protein tau, which
regulates microtubule dynamics and assembles microtubules into
parallel arrays within axons. The H1 and H2 haplotypes represent
two distinct clades of subhaplotypes ensued from an inversion of
w900 kb on chromosome 17q21, spanning the entire MAPT coding
region [13], and are tagged, among others, by genotypes at two
SNPs: rs9468 and rs1800547 [14]. The H1 haplotype has been
signiﬁcantly associated with an increased risk for a number of
neurodegenerative diseases [13]. Several studies proposed the
MAPT H1 haplotype as susceptibility factor also for PD [15e17].
Associations of SNCA and MAPT with PD have been replicated
not only in candidate gene studies, but also in several independent
genome-wide association studies (GWAS), again suggesting the
two genes as strong susceptibility factors for idiopathic PD in
different populations [18e22]. These data were further conﬁrmed
by a very recent meta-analysis of PD GWAS [23]. However, no
extensive investigations, including SNCA-MAPT interaction or gene-
environment analyses, have been performed on the Italian
population.
The present study was designed to investigate the role of SNCA
and MAPT as susceptibility genes for PD in a large and well-
characterized Italian population, and to evaluate possible interac-
tions between the two loci.2. Methods
2.1. Subjects
We studied 904 subjects with a diagnosis of PD and 891 controls who had
contributed to the DNA Bank of the Parkinson Institute, Istituti Clinici di Perfezio-
namento, Milan, Italy (“Human genetic bank of patients affected by Parkinson
disease and parkinsonisms”; http://www.parkinson.it/dnabank.html).
All patients were examined by movement disorder neurologists. The clinical
diagnosis of PD was established according to the UK Parkinson Disease Society Brain
Bank criteria ([24], and references therein) and required the presence of bradyki-
nesia and at least one symptom among the followings: resting tremor, rigidity or
postural instability, a positive response to dopaminergic therapy, and absence of
atypical features or other causes of parkinsonism. The age at which the patient ﬁrst
noticed a PD-related symptom was considered the age of onset of the disease.
Patients were classiﬁed as “familial” if at least one among their 1st or 2nd degree
relatives had a formal diagnosis of PD. The remaining patients were classiﬁed as
“sporadic”.
The LRRK2 G2019S missense substitution was screened in all subjects [25],
whereas the PRKN gene was analyzed in all 62 PD patients with onset before the age
of 40 [26]. LRRK2 and PRKN mutation carriers were excluded from this study.
Control subjects, unrelated to the patients and with negative family history for
movement disorders, were recruited among spouses and care-givers. With the
exception of 4 patients, originating from Argentina, Albania, and Greece, all the
affected subjects and controls were of Italian origin.
At the time of blood sampling, a standardized questionnaire, documenting
medical diagnoses, lifestyle, and medications was ﬁlled in for all cases and controls.
Smoking status was deﬁned as current, former, or never smoker on the basis of self-
reports (current and former smokers were grouped together in the single category of
smokers in the statistical analyses). Coffee consumption was quantiﬁed on the basis
of self-reports, with no consumption being deﬁned as the intake of up to 2 coffee/
day, and consumption as more than 2 coffee/day.The study was approved by the local Ethics Committee. All participants signed
an informed consent.
2.2. Genotyping assays
Genomic DNA extraction was performed from peripheral blood using a semi-
automated extractor (QuickGene DNA Whole Blood Kit; FUJIFILM Europe GmbH
Life Science, Düsseldorf, Germany). DNA samples were quantiﬁed using a Bio-
Photometer (Eppendorf AG, Hamburg, Germany), standardized for concentration,
and arrayed into 96-deep-well plates.
The SNCA Rep1 region was PCR ampliﬁed from genomic DNA using the primer
couple: 50-GACTGGCCCAAGATTAACCA-30 (ﬂuorescently labeled with 6-FAM) and 50-
CCTGGCATATTTGATTGCAA-30 (SigmaeAldrich Co., St Louis, MO, USA). PCR products
were resolved by capillary electrophoresis on an ABI-3130XL Genetic Analyzer
(Applied Biosystem, Foster City, CA, USA). Allelic sizes were assessed using the
GeneMapper v4.0 software (Applied Biosytems). On the basis of the length of PCR
products, Rep1 alleles were coded as follows: allele 1 ¼ 259 bp, allele 2 ¼ 261 bp,
allele 3 ¼ 263 bp, according to one of the previously described nomenclatures [4].
Fourteen biallelic markers were selected within the SNCA (12 SNPs) and MAPT (2
SNPs) gene regions. The 12 SNCAmarkers were chosen either on the basis of previous
associationdata inCaucasianpopulations [10,27], or fromdbSNP (http://www.ncbi.nlm.
nih.gov/projects/SNP/); in all cases, SNPs showed a minor allele frequency of at least
w20% in the general population, andwere selected in order to both assure an adequate
coverageof theSNCA locusandmeet thestrictcriteria forprobedesignof thegenotyping
assay. The 2MAPT SNPs were chosen because both tagged the H1/H2 haplotypes.
Genotypes were determined using the Applied Biosystems SNPlex assay [28].
Detection was performed on an ABI-3130XL Genetic Analyzer; data interpretation
was performed with the GeneMapper software. Reproducibility was assessed by
comparing replicated samples.
2.3. Statistical analyses
2.3.1. Phenotypic data
The dependence of disease risk (the response variable) on potential explanatory
factors [age, sex, smoking status, and coffee consumption] was analyzed with
a conditional logistic regression model and statistical signiﬁcance was tested using
the likelihood ratio test andWald’s test [29]. In the regression, the response variable
was set to 1 in cases and to 0 in controls. The effect of each explanatory factor was
expressed as the odds ratio (OR) and 95% conﬁdence interval (CI) computed from the
corresponding estimated regression coefﬁcient in the model. Unadjusted ORs were
obtained by using a model that included only the factor of interest; adjusted ORs
were obtained by using a model that included the factor of interest plus all of the
remaining factors. All procedures were performed using the R program, version
2.10.1 (http://www.r-project.org/).
2.3.2. Genetic data
Allele and genotype frequencies of the Rep1marker were calculated by using the
Genepop program, option 5 (http://genepop.curtin.edu.au/). The same software,
option1,wasused to test thedeviation from theHardyeWeinberg equilibrium (HWE).
Allelic and genotypic frequencies of Rep1 were compared by means of a c2 statistic,
generated through theMonte Carlo approach using the CLUMP program [30]. CLUMP
uses theMonte Carlo procedure by measuring the differences in frequencies between
cases and controls, and then produces multiple simulated datasets to calculate how
many times the observed differencesmight be generated by chance if the frequencies
were the same. Signiﬁcancewas assessed by carrying out 10,000 simulations. The use
of theMonteCarlo simulation avoids theneed for theBonferroni (orothers) correction.
Analysis of deviation from HWE, genotyping success rate, allelic and genotypic
frequencies, and association with PD of SNPs in SNCA and MAPT were performed
using the PLINK software (http://pngu.mgh.harvard.edu/wpurcell/plink/). For each
SNP, standard caseecontrol analyses on allele and genotype frequency data were
performed with c2 statistics (Fisher exact test). In the text, all P-values for individual
SNPs, OR, and 95% CI are presented as non-corrected for multiple testing and refer to
the minor allele. Associations were also retested adjusting the logistic regression
models for sex, smoking, and coffee consumption, previously tested for association
with the disease, using the R software.
For SNCA, the LD structure was determined from our SNP data using the Hap-
loview v4.0 program (http://www.broadinstitute.org/haploview). LD blocks were
deﬁned using the “spine of LD” setting. Haplotype-based association analysis was
performed considering only those SNPs mapping within the same LD block, using
the PLINK software.
Power estimates indicated that, if each analyzed polymorphism (disease allele
frequency of 10%) were to directly confer a 1.5-fold increase in the relative risk of PD,
the case and control groups used in this research would be of sufﬁcient size to have
99% power to detect a signiﬁcant association at the 0.05 level.
2.3.3. Secondary analyses
All secondary analyses were accomplished using the PLINK software. In partic-
ular, a pair-wise epistasis analysis of the 15 genotyped polymorphisms was per-
formed using the “–epistasis” option, which provides a logistic regression test for
Table 2
Analysis of allele and genotype frequency differences between PD cases and controls
for the Rep1 polymorphism.
SNCA Rep1 PD cases N (%) Controls N (%) Allele distribution
Alleles
259 468 (27.3%) 496 (30.01%) T1: p ¼ 0.18
261 1157 (67.5%) 1064 (64.56%) T2: p ¼ 0.18
263 89 (5.2%) 88 (5.43%) T3: p ¼ 0.072
Total 1714 (100%) 1648 (100%) T4: p ¼ 0.16
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interactions.
A case-only analysis was also performed. For both analyses, only pairs of SNPs on
different chromosomes (i.e. in linkage equilibrium) were considered.
As for gene-environment interaction, we focused on smoking and coffee
consumption, because their individual inverse associations with PD are well
established [31]. A Breslow-Day test of homogeneity of OR for the identiﬁcation of
possible interactions between SNCA/MAPT with smoking and coffee consumption
was performed. In this case, clusters were stratiﬁed according to the presence/
absence of the habit for each SNP, and their disease/gene ORs compared.SNCA Rep1 PD cases N (%) Controls N (%) Genotype distribution
Genotypes
259/259 83 (9.68%) 74 (9%)
259/261 282 (32.91%) 331 (40.17%) T1: p ¼ 0.05
259/263 20 (2.33%) 17 (2.06%) T2: p [ 0.026
261/261 406 (47.38%) 334 (40.53%) T3: p [ 0.002
261/263 63 (7.35%) 65 (7.88%) T4: p [ 0.014
263/263 3 (0.35%) 3 (0.36%)
Total 857 (100%) 824 (100%)
Alleles having frequencies less than 0.5% were excluded from analysis.
N, number of PD cases or controls.
T1, Pearson’s c2 statistic of the “raw” contingency table.
T2, the c2 statistic of a table with rare alleles/genotypes grouped together to prevent
small expected cell counts.
T3, the largest of the c2 statistics of 2  2 tables, each of which compares one allele/
genotype with the rest grouped together.
T4, the largest of the c2 statistics of all possible 2  2 tables, comparing any
combination of alleles/genotypes with the rest.
Signiﬁcant p values are indicated in bold.3. Results
3.1. PD patients’ characteristics
Demographics of the subjects included in this study are showed
in Table 1.
Among the 904 PD patients, 543 (60.1%) were male, the mean
age at onset was 56.1 years (range 14e82), and the mean disease
duration was 10.6 years (range 4e42). Two hundred and eighty
nine patients were classiﬁed as “familial”, the remaining subjects as
“sporadic”.
Coffee consumption and cigarette smoking habits were both
more represented in controls than in cases, and showed a strong
protective effect [OR ¼ 0.54 (95% CI ¼ 0.42e0.69) and OR ¼ 0.68
(95% CI ¼ 0.53e0.88), respectively]; also sex difference was very
marked, but this is ascribable to a recruitment bias, as most controls
are partners of PD patients.3.2. Single-marker association analysis with SNCA and MAPT
An association analysis on the entire PD cohort was performed
by genotyping 15 polymorphic markers: the Rep1 microsatellite
located in the 50 regulatory region of SNCA, 12 SNPs covering the
whole SNCA gene, and 2 SNPs, located w50 kb apart from each
other, both tagging the MAPT H1/H2 haplotypes.
The mean genotyping success rate was 90.2% and the accuracy
was >99%, according to random duplicated genotyping of 5% of
samples. Only one SNP, rs356221, did not result in HWE and was
excluded from further analysis.
3.2.1. The Rep1 polymorphism
Genotyping of the Rep1 polymorphism revealed three
predominant alleles (length: 259 bp, 261 bp, and 263 bp) (Table 2).
Before the association test, rare alleles with frequencies less than
0.5% were excluded from the analysis, as previously described [10].
Association was ﬁrst tested using CLUMP. Rep1 did not
demonstrate association in the allelic analysis, but showed a robustTable 1
Characteristics of PD patients and control subjects.
Cases (n ¼ 904) Controls (n
Age (y  SD)a 66.6  10.9 62.4  14.
Mean onset age (y  SD)b 56.1  11.0 n.a.
Mean disease duration (y  SD) 10.6  5.9 n.a.
Familial cases (%) 32 n.a.
Female (%) 39.9 65.5
Coffee consumption (%)c
No (up to 2 coffee/day) 71.2 56.6
Yes (more than 2 coffee/day) 28.8 43.4
Smoking (%)c
No 63.8 59.2
Yes þ former 36.2 40.8
Data are shown either as mean  standard deviation (SD) or as %; y, years; n.s., not sign
a Age at blood draw.
b Age at which the patient noticed the ﬁrst PD symptoms.
c Data are based on patients and controls self report. Current and former smokers weassociation in the genotypic analysis, being the three c2 statistics
T2, T3, and T4 signiﬁcant, and the forth one (T1) close to the
signiﬁcance level (Table 2). In particular, frequency differences in
cases vs. controls were striking for the 259/261 and 261/261
genotypes (w33% vs. 40%, and 47.4% vs. 40.5%, respectively). Hence,
association of Rep1 with PD was also analyzed assuming a biallelic
model, only considering individuals carrying the 259 and/or 261
alleles (w90% of cases and controls). This approach again revealed
no association in the allelic analysis (adjusted P-value ¼ 0.398)
(Table 3), but evidenced signiﬁcant associations both in the geno-
typic analysis (P ¼ 0.005) and in the analysis performed assuming
a dominant model of inheritance (P¼ 0.004; the 261 bp-long being
the risk allele) (Supplementary Table 1).
3.2.2. SNPs in SNCA
Seven SNPs mapping in the SNCA region showed a signiﬁcant
association with the disease; three retained their signiﬁcance even
after correction for covariates (Table 3). One (rs2737029) of these
resulted associated with an increased risk of PD (OR ¼ 1.22, 95%
CI ¼ 1.03e1.44), whereas the remaining two showed a similar
strength of association and a protective effect (top SNP rs356186,
P ¼ 0.005, OR ¼ 0.74, 95% CI ¼ 0.59e0.91) (Table 3). Interestingly,¼ 891) Unadjusted OR (95% CI) Adjusted OR (95% CI)
6 n.s. e
e e
e e
e e
0.35 (0.29e0.42) 0.31 (0.25e0.40)
0.53 (0.42e0.67) 0.54 (0.42e0.69)
0.82 (0.67e1.00) 0.68 (0.53e0.88)
iﬁcant; n.a., not applicable.
re aggregated in the single category of smokers.
Table 3
Allelic frequencies and association test of Rep1 and selected SNPs in the SNCA and MAPT regions.
Chr bpa Locus SNP Major/minor
Allele
MAF cases MAF
controls
Unadjusted analysis Adjusted analysisb
P value OR (95% CI) P value OR (95%CI)
4 90847150 SNCA rs356180 T/C 0.34 0.31 0.051 1.16 (1.00e1.36) 0.227 1.12 (0.93e1.36)
4 90856624 SNCA rs356219 G/A 0.41 0.38 0.027 1.17 (1.02e1.35) 0.077 1.17 (0.98e1.39)
4 90860363 SNCA rs356220 T/C 0.41 0.37 0.023 1.18 (1.02e1.36) 0.060 1.19 (0.99e1.42)
4 90876514 SNCA rs3775423 T/C 0.08 0.07 0.575 1.08 (0.83e1.40) 0.210 1.23 (0.89e1.69)
4 90885064 SNCA rs356203 G/A 0.42 0.38 0.033 1.16 (1.01e1.34) 0.085 1.16 (0.98e1.38)
4 90906950 SNCA rs356192 C/T 0.28 0.26 0.320 1.08 (0.92e1.27) 0.355 1.09 (0.90e1.33)
4 90924387 SNCA rs356186 A/G 0.17 0.22 3.08 3 10L04c 0.73 (0.61e0.87) 0.005 0.74 (0.59e0.91)
4 90930793 SNCA rs2737029 C/T 0.44 0.40 0.015 1.19 (1.03e1.36) 0.020 1.22 (1.03e1.44)
4 90948625 SNCA rs2197120 A/G 0.18 0.23 7.20 3 10L04c 0.75 (0.63e0.89) 0.007 0.75 (0.61e0.92)
4 90959901 SNCA rs2737020 C/T 0.26 0.28 0.151 0.89 (0.77e1.04) 0.391 0.92 (0.76e1.11)
4 90979851 SNCA rs2583988 T/C 0.31 0.27 0.029 1.19 (1.02e1.38) 0.118 1.17 (0.96e1.41)
4 90986232 SNCA Rep1 259/261 0.29 0.32 0.046 0.85 (0.73e1.00) 0.398 0.92 (0.76e1.11)
17 41407682 MAPT rs1800547 G(H2)/A(H1) 0.19 0.24 4.63 3 10L04c 0.74 (0.62e0.87) 0.002c 0.72 (0.58e0.89)
17 41457408 MAPT rs9468 C(H2)/T(H1) 0.19 0.24 4.23 3 10L04c 0.71 (0.60e0.83) 4.62 3 10L04c 0.69 (0.56e0.85)
Rep1 was evaluated assuming a biallelic model, by considering only the two most frequent alleles (259 and 261 bp).
Chr, chromosome; MAF, minor allele frequency; L, 95% CI lower limit; U, 95% CI upper limit.
Signiﬁcant p-values are indicated in bold.
a Position is given according to UCSC Genome Browser [http://genome.ucsc.edu/, Mar. 2006 (NCBI36/hg18) assembly].
b Adjusted for sex, smoke, and coffee consumption.
c Signiﬁcant even after the conservative Bonferroni correction for 14 SNP tests.
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tion in the genotypic analysis (Supplementary Table 1).
3.2.3. SNPs in MAPT
Both selected MAPT SNPs showed a strong signal of association
(top SNP: rs9468, P ¼ 0.00046, OR ¼ 0.69, 95% CI ¼ 0.56e0.85)
(Table 3). The tagged H1 haplotype was over-represented in
patients with respect to controls (81% vs. 76%; OR ¼ 1.39 and 1.45
for rs1800547 and rs9468, respectively). The association was also
conﬁrmed by genotype distribution analysis (Supplementary
Table 1).3.3. LD blocks and haplotype analyses of the SNCA locus
LD within SNCA was evaluated using Haploview. The whole
region showed an overall strong degree of LD; nonetheless, 2
distinct haplotype blocks could be deﬁned, one covering a 37 kb-
long region and corresponding to the 50 end of the gene, the other
spanning from intron 4 to the 30 region of SNCA (w83 kb) (Fig. 1).
Haplotype analysis was accomplished considering only SNPs
mapping within the same LD block. The CACCATAA haplotype,
composed of SNPs rs356180-rs356219-rs356220-rs3775423-
rs356203-rs356192-rs356186-rs2737029 (block 1), was less rep-
resented in PD cases (13.9%) respect to controls (19.6%), thus
resulting a protective haplotype (P ¼ 1.29  1005). In block 2,
a second protective haplotype was found (16.1 and 21.1% in patients
and controls; P ¼ 2  1004), together with two predisposing
haplotypes, whose frequency is however below 2% (Supplementary
Table 2).3.4. Geneegene and gene-environment interaction analyses
Considering that some evidence suggests that genetic variants
in SNCA and MAPT could interact in modulating risk for PD [14], an
attempt to evaluate geneegene interactions was performed. All
pair-wise combinations of SNPs in linkage equilibrium (i.e. lying
on different chromosomes) were tested, but no allelic epistasis
was observed (Supplementary Table 3). A similar analysis, per-
formed only on cases, did not show any signiﬁcant interaction
(Supplementary Table 3).Because both coffee consumption and smoking status showed
a signiﬁcant protective effect against PD, a preliminary test for
homogeneity was used to identify their possible interactions with
genotyped polymorphisms. However, no tendency to heterogeneity
was detected between groups stratiﬁed according to the presence/
absence of the habit for any SNP (lowest P-value ¼ 0.18) (data not
shown). No further analysis was hence attempted.
4. Discussion
Many efforts have been focused on the identiﬁcation of common
variants conferring susceptibility to PD: replication studies on
candidate genes, GWAS, and large meta-analyses provide a strong
support for a role of SNCA andMAPT in the genetic predisposition to
the disease [4,5,9e23]. Considering that no extensive data on the
Italian population are currently available, we investigated the
involvement of SNCA andMAPT genetic variants in PD susceptibility
in our cohort of 904 Italian PD patients and 891 controls.
Concerning the SNCA gene, we ﬁrst analyzed the Rep1 poly-
morphism, conﬁrming its associationwith PD and emphasizing the
role of the 261 bp-long allele as a risk factor for the disease, espe-
cially under the dominant model of inheritance. Indeed, the large
meta-analysis performed by Maraganore and colleagues [5]
showed a robust association of both the Rep1 259 bp-long allele
(protective effect) and the 263 bp-long allele (predisposing effect),
but not of the 261 bp-long allele. The lack of association of the Rep1
261 bp-long allele in the meta-analysis could be due to the large
ﬂuctuation in its frequencies observed in the analyzed populations
(range: 62e71% and 61e72% in cases and controls, respectively). In
any case, our results well correlate with those reported by Cronin
and colleagues, who studied the effects of three distinct Rep1
variants in the brains of human SNCA transgenic mice. In animals
homozygous for the risk allele (261 bp), they observed a 1.7-fold
increase of the SNCA mRNA and a 1.25-fold increase in the
protein level, suggesting that this allele may mimic SNCA locus
multiplication [7].
Besides Rep1, we performed an association analysis between 12
SNPs covering the whole SNCA gene region and PD. We found
strong signals of association clustered in a region ofw24 kb located
in the middle of SNCA intron 4 (ﬂanking SNPs: rs356186 and
rs2197120; Table 3 and Fig. 1), where only few putative enhancers
Fig. 1. LD structure of the SNCA locus. The structure of the SNCA gene is shown (drawn to scale; exons are represented by boxes, introns by horizontal lines, which also indicate the
transcriptional direction of the gene). At the top of the gene, the ruler indicates the gene size, whereas numbers below the ruler depict the position within chromosome 4 (UCSC
Genome Browser, Mar. 2006 release, NCBI36/hg18). Genotyped polymorphisms are listed, and their locations are shown by lines relative to the SNCA gene. Below the gene scheme,
associated haplotypes identiﬁed in this (continuous) or previous (dashed) works are indicated as horizontal lines; the overlapping region is shaded in gray; numbers beside
previously-reported haplotypes correspond to: 1) [9]; 2) [10]; 3) [19]; 4) [18]. Only SNPs shared among our and other haplotypes are indicated with a vertical hyphen in haplotypes
1e4; capital letters indicate alleles exerting a protective effect, small letters indicate alleles exerting a predisposing effect. For the Rep1 microsatellite, only the two most frequent
alleles were considered: the 259 bp-long allele was named 1, the 261 bp-long allele was named 2. In the lower part of the ﬁgure, the LD structure of the SNCA locus is shown. Pair-
wise LD values, estimated for the genotyped SNPs, are represented by boxes. The standard color scheme of Haploview was used to display the strength of LD: black indicates strong
LD, grey intermediate, whereas white denotes no LD. r2 values are shown within the boxes.
L. Trotta et al. / Parkinsonism and Related Disorders 18 (2012) 257e262 261are reported (see the ENCODE track, UCSC Genome browser, http://
genome.ucsc.edu/). These signals were further conﬁrmed by
haplotype analysis, which revealed the existence of a strong
protective allele spanning from the SNCA 30 ﬂanking region up to
intron 4 (Fig. 1). Our results corroborate the hypothesis of a major
susceptibility block located in the 30 region of SNCA in Caucasian
populations, as reported in other studies [10,11], but extend the
putative susceptibility region toward intron 4, as previously
hypothesized [9,10]. Marker saturation of this overlooked region
could provide more accuracy in deﬁning LD blocks and haplotypes,thus hopefully facilitating the identiﬁcation of functional variants
underlying PD susceptibility.
Since the discovery of the involvement of MAPT in neurological
disorders [13], several studies investigated its possible involvement
in PD, especially in the light of in-vitro studies suggesting an
interaction between the MAPT-encoded tau protein and a-synu-
clein [32]. Although initially controversial, mounting evidence now
suggests the H1 haplotype as a strong PD susceptibility factor
[18e23]. The association study performed in our population further
conﬁrms the role of the H1-clade as risk allele: strong signals of
L. Trotta et al. / Parkinsonism and Related Disorders 18 (2012) 257e262262associations were observed both in the allelic and in the genotypic
analyses. In particular, the associationwe observed between the H1
haplotype (tagged by rs9468) and PD was highly signiﬁcant
(P ¼ 4.62  104), and the effect size was even stronger than that
observed for the best associated SNP in SNCA (OR ¼ 1.45, 95%
CI ¼ 1.18e1.78 vs. OR ¼ 1.35, 95% CI ¼ 1.1e1.69 forMAPT and SNCA).
Given our results both on SNCA and MAPT, we attempted to
evaluate potential geneegene and gene-environment interactions.
No pair-wise interaction was observed between polymorphisms of
the two genes, with no evidence suggesting cumulative, syner-
gistic, or antagonistic effects, as for the majority of other Caucasian
populations ([33] and references therein). Only a few association
studies have examined gene-environment interactions in PD, the
most studied environmental exposures being coffee drinking and
cigarette smoking. Cumulative and interactive effects of cigarette
smoking and gene polymorphisms in NOS1 (neuronal nitric oxide
synthase), NOS2A (inducible nitric oxide synthase), and SNCAwere
reported to modulate the risk of PD [31,34], whereas a signiﬁcant
interaction was observed between the APOE gene and coffee intake
[34]. Our analysis, though performed on a relatively large number
of PD cases and controls, failed to observe any interaction, again
underscoring the need for larger association studies to deﬁne the
role of gene-environment interactions in the development of PD.
In conclusion, our results strongly conﬁrm the susceptibility role
of SNCA and MAPT genes in idiopathic PD in the Italian population,
and add a further piece of information toward the future identiﬁ-
cation of the actual functional variants underlying these associa-
tions and the construction of a cumulative score of genetic variants
to predict individual disease risk.
Acknowledgments
The DNA samples were from the ‘‘Human Genetic Bank of
Patients Affected by Parkinson Disease and Parkinsonisms’’ of the
Parkinson Institute, Istituti Clinici di Perfezionamento, Italy (http://
www.parkinson.it/dnabank.htm). This biobank is supported by the
Italian Telethon Foundation (grant n. GTB07001) and by the “Fon-
dazione Grigioni per il Morbo di Parkinson”.
The study was ﬁnanced by a PUR 2009 grant (Programma del-
l’Università per la Ricerca) to R.A. (Grant # 2009-ATE-0345).
Appendix. Supplementary material
Supplementary material associated with this article can be
found, in the online version, at doi:10.1016/j.parkreldis.2011.10.014.
References
[1] Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009;373:2055e66.
[2] Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic
susceptibility factors. Hum Mol Genet 2009;18:R48e59.
[3] Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr
Psychiatry Neurol 2010;23:228e42.
[4] Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M,
et al. Alpha-synuclein gene haplotypes are associated with Parkinson’s
disease. Hum Mol Genet 2001;10:1847e51.
[5] Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, et al.
Collaborative analysis of alpha-synuclein gene promoter variability and Par-
kinson disease. JAMA 2006;296:661e70.
[6] Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1
repeat upstream of the alpha-synuclein gene (SNCA) on transcription in
a cell culture luciferase reporter system. Hum Mol Genet 2001;10:3101e9.
[7] Cronin KD, Ge D, Manninger P, Linnertz C, Rossoshek A, Orrison BM, et al.
Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates
human alpha-synuclein in transgenic mouse brain. Hum Mol Genet 2009;18:
3274e85.[8] Chiba-Falek O, Kowalak JA, Smulson ME, Nussbaum RL. Regulation of alpha-
synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding
to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am J Hum
Genet 2005;76:478e92.
[9] Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, et al. Multiple
candidate gene analysis identiﬁes alpha-synuclein as a susceptibility gene for
sporadic Parkinson’s disease. Hum Mol Genet 2006;15:1151e8.
[10] Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, et al. Multiple
regions of alpha-synuclein are associated with Parkinson’s disease. Ann
Neurol 2005;57:535e41.
[11] Pankratz N, Nichols WC, Elsaesser VE, Pauciulo MW, Marek DK, Halter CA,
et al. Alpha-synuclein and familial Parkinson’s disease. Mov Disord 2009;24:
1125e31.
[12] Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, et al. SNCA
variant associated with Parkinson disease and plasma alpha-synuclein level.
Arch Neurol 2010;67:1350e6.
[13] Kalinderi K, Fidani L, Bostantjopoulou S. From 1997 to 2007: a decade journey
through the H1 haplotype on 17q21 chromosome. Parkinsonism Relat Disord
2009;15:2e5.
[14] Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, et al. Tau
and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease.
Ann Neurol 2007;62:145e53.
[15] Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, et al.
Haplotypes and gene expression implicate the MAPT region for Parkinson
disease: the genepd study. Neurology 2008;71:28e34.
[16] Zabetian CP, Hutter CM, Factor SA, Nutt JG, Higgins DS, Grifﬁth A, et al.
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson’s
disease. Ann Neurol 2007;62:137e44.
[17] Refenes N, Bolbrinker J, Tagaris G, Orlacchio A, Drakoulis N, Kreutz R. Role of
the H1 haplotype of microtubule-associated protein tau (MAPT) gene in Greek
patients with Parkinson’s disease. BMC Neurol 2009;9:26.
[18] Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. Genome-
wide association study identiﬁes common variants at four loci as genetic risk
factors for Parkinson’s disease. Nat Genet 2009;41:1303e7.
[19] Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al.
Genome-wide association study reveals genetic risk underlying Parkinson’s
disease. Nat Genet 2009;41:1308e12.
[20] Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, Lambert JC, et al.
Genome-wide association study conﬁrms BST1 and suggests a locus on 12q24
as the risk loci for Parkinson’s disease in the European population. Hum Mol
Genet 2011;20:615e27.
[21] Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G, et al.
Dissection of the genetics of Parkinson’s disease identiﬁes an additional
association 5’ of SNCA and multiple associated haplotypes at 17q21. Hum Mol
Genet 2011;20:345e53.
[22] Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, et al.
Genome-wide association study conﬁrms SNPs in SNCA and the MAPT region
as common risk factors for Parkinson disease. Ann Hum Genet 2010;74:
97e109.
[23] Consortium IPDG. Imputation of sequence variants for identiﬁcation of genetic
risks for Parkinson’s disease: a meta-analysis of genome-wide association
studies. Lancet 2011;377:641e9.
[24] Hughes A, Daniel S, Lees A. Improved accuracy of clinical diagnosis of Lewy
body Parkinson’s disease. Neurology 2001;57:1497e9.
[25] Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons E, et al. LRRK2
G2019S mutation and Parkinson’s disease. A clinical, neuropsychological and
neuropsychiatric study in a large italian sample. Parkinsonism Relat Disord
2006;12:410e9.
[26] Sironi F, Primignani P, ZiniM, Tunesi S, RuffmannC, Ricca S, et al. Parkin analysis
in early onset Parkinson’s disease. Parkinsonism Relat Disord 2008;14:326e33.
[27] Ross OA, Gosal D, Stone JT, Lincoln SJ, Heckman MG, Irvine GB, et al. Familial
genes in sporadic disease: common variants of alpha-synuclein gene associate
with Parkinson’s disease. Mech Ageing Dev 2007;128:378e82.
[28] Tobler AR, Short S, Andersen MR, Paner TM, Briggs JC, Lambert SM, et al. The
SNPlex genotyping system: a ﬂexible and scalable platform for snp geno-
typing. J Biomol Tech 2005;16:398e406.
[29] Breslow NE, Day NE. Statistical methods in cancer research. In: The design and
analysis of cohort studies, vol. ii. IARC Sci Publ; 1987. p. 1e406.
[30] Sham PC, Curtis D. Monte Carlo tests for associations between disease and
alleles at highly polymorphic loci. Ann Hum Genet 1995;59:97e105.
[31] Gao HM, Hong JS. Gene-environment interactions: key to unraveling the
mystery of Parkinson’s disease. Prog Neurobiol 2011;94:1e19.
[32] Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al.
Initiation and synergistic ﬁbrillization of tau and alpha-synuclein. Science
2003;300:636e40.
[33] Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, et al.
Independent and joint effects of the MAPT and SNCA genes in Parkinson
disease. Ann Neurol 2011;69:778e92.
[34] McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, et al. Exploring
gene-environment interactions in Parkinson’s disease. Hum Genet 2008;123:
257e65.
